Pfizer and Nektar reach agreement on Exubera

San Carlos-based Nektar Therapeutics (NKTR) has resolved a contract dispute with Pfizer Inc. (PFE) over its line of inhaled insulin products, the companies announced Tuesday.

Pfizer will pay Nektar $135 million to satisfy its obligations for contracts relating to Exubera, an inhaled insulin product, and agreed to transfer its remaining right to the product if Nektar finds another partner for its development and marketing, the compay said in a statement.

Pfizer announced it would discontinue Exhubera last month due to disappointing sales, taking a $2.8 billion charge in the third quarter as a result, according to the Associated Press.

The companies said they will continue to work together on PEGylated human growth hormone therapy for short stature and growth problems.

Just Posted

New SFMTA director’s tweets show aversion to free parking, cars

The City’s new transit leader has a bumpy relationship with cars. Jeffrey… Continue reading

Advocates say Academy of Art deal ignores needs of students with disabilities

The needs of students with disabilities are being ignored in a proposed… Continue reading

City stalls request for more parking for 911 dispatchers, citing ‘Transit First’ policy

SFMTA board says city staff should be ‘leading by example,’ discouraged from driving

Recall effort against Fewer panned as ‘PR stunt’

Signature drive inspired by anti-SFPOA chant faces ‘procedural hurdles,’ little support

SF to ward off emerging technology dangers by launching new regulatory office

Board president Norman Yee says innovation must ‘provide a net common good’

Most Read